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Case Series

The Efﬁcacy of Lenvatinib Plus Everolimus in
Patients with Metastatic Renal Cell Carcinoma
Exhibiting Primary Resistance to Front-Line
Targeted Therapy or Immunotherapy
Lana Hamieh,1,2 Rachel L. Beck,1 Valerie H. Le,1 James J. Hsieh1
Abstract
Background: Patients with primary refractory metastatic renal cell carcinoma (mRCC) have a dismal prognosis and
poor response to subsequent treatments. While there are several approved second-line therapies, it remains critical to
choose the most effective treatment regimen. Patients and Methods: We identiﬁed 7 patients with clear cell mRCC
who had primary resistance to vascular endothelial growth factor (VEGF)-targeted tyrosine kinase inhibitors (TKIs) or
immune checkpoint inhibitor (ICI) combination therapy. The patients were treated with lenvatinib (a multitargeted TKI)
plus everolimus (a mammalian target of rapamycin inhibitor). Among these 7 patients, 2 had prior TKI therapy, 3 had
prior ICI therapy, and 2 had prior TKI and ICI therapy. We collected the patients' clinical characteristics, molecular
proﬁles, treatment durations, and toxicity outcomes. Results: The median time to progression on prior therapies was
1.5 months. Lenvatinib plus everolimus was used either as a second-line (n ¼ 4) or third-line (n ¼ 3) therapy. As best
responses, 3 patients had partial responses and 3 achieved stable disease. Patients were followed for 17 months;
progression-free survival ranged from 3 to 15 months, and overall survival ranged from 4 to 17 months. Conclusion:
These 7 cases provide real-world data for the use of lenvatinib plus everolimus in patients with mRCC with primary
resistance to ﬁrst-line VEGF-targeted TKIs or ICI combination therapy.
Clinical Genitourinary Cancer, Vol. 18, No. 4, 252-7 ª 2020 The Author(s). Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Immune checkpoint inhibitor, Kidney cancer, mTOR inhibitor, Primary refractory, Second-line therapy tyrosine
kinase inhibitor

Introduction
The treatment landscape for metastatic renal cell carcinoma
(mRCC) is constantly changing with the continuous approval of
new ﬁrst-line and second-line therapies.1-4 Preferred ﬁrst-line
treatments for clear cell mRCC include vascular endothelial
growth factor (VEGF)-targeted tyrosine kinase inhibitors (TKIs; eg,
sunitinib, pazopanib, cabozantinib) and immune checkpoint inhibitor (ICI) combination therapies (eg, ipilimumab plus nivolumab, axitinib plus pembrolizumab).5 However, a signiﬁcant
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proportion (approximately 20%) of patients have tumors that
progress during ﬁrst-line treatments and necessitate subsequent
therapies.6-9
Several regimens have been approved in the second-line setting
with the following preferred treatment options: cabozantinib,
nivolumab, lenvatinib plus everolimus, and axitinib.4 However,
given the changing treatment paradigm of mRCC favoring immunotherapy over targeted therapy, the approval of second-line therapies based on clinical trials using different control arms and in
different ﬁrst-line settings, and the diverse patient population in
terms of risk group and histology, it has become increasingly
challenging for clinicians to determine the optimal subsequent line
of treatment.
Patients refractory to ﬁrst-line mRCC therapy with either targeted therapy or immunotherapy are of special interest, given their
dismal prognosis due to poor response to subsequent therapy with
VEGF-targeted TKIs or mammalian target of rapamycin (mTOR)
inhibitors.6-9 Thus, careful selection of second-line treatment is

1558-7673/ª 2020 The Author(s). Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.clgc.2020.03.003

imperative. Circumventing the mechanisms underlying resistance
to VEGF-targeted TKIs using angiogenic escape through the upregulation of ﬁbroblast growth factor (FGF)-associated signaling
has been demonstrated.10 Therefore, simultaneous inhibition of
VEGF and FGF pathways using a multitargeted TKI is a rational
approach that has been drawing substantial interest, and evidence
of its efﬁcacy has been reported.10,11 Lenvatinib is a potent multitargeted TKI that inhibits VEGF receptors 1-3, FGF receptors 14, platelet-derived growth factor receptor-b, RET, and KIT.12 In
addition to the VEGF and FGF pathways, the mTOR pathway
also has been implicated in the development of RCC.13-16 In the
United States, a regimen combining lenvatinib and everolimus (an
mTOR inhibitor) has been approved as a second-line treatment in
patients with mRCC who have failed targeted therapy with a
antiangiogenic TKI.17,18
Patients whose tumors are refractory to ﬁrst-line therapy with the
combination of the ICIs ipilimumab plus nivolumab have yet to be
studied. However, because more patients are receiving the ICI
combination as ﬁrst-line therapy, and given the lack of guidance on
second-line therapies, understanding patient outcomes with subsequent therapy is paramount to help guide optimal clinical decisions.
In this 7-patient case series, we report the characteristics and the
outcomes of patients with clear cell mRCC whose tumors were
refractory to ﬁrst-line therapy with TKIs or ICIs and who were
subsequently treated with lenvatinib plus everolimus.

Materials and Methods
We identiﬁed patients who were refractory to ﬁrst-line therapy
(VEGF-targeted TKI and/or ICI combination therapy) and who
were subsequently treated with lenvatinib plus everolimus. All patients were treated by a single provider (J.H.) at Barnes Jewish
Hospital/Washington University School of Medicine and provided
informed consent for the study of their tumors and publication of
their associated clinical data (Washington University HRPO
#201411135).
Clinical characteristics, treatment exposures, toxicities, and outcomes were collected from the electronic medical records. The
choices of treatment and response assessment were at the discretion
of the treating provider.
In most patients, tumor and germline DNA were analyzed using
massive parallel sequencing with the Tempus|xO Onco-seq panel
(Tempus, Chicago, IL). The Tempus|xO Onco-seq panel consists
of 1714 cancer-related genes and detects clinically relevant genomic
alterations (genomic variants as well as copy number variations).
Tumor specimens were also analyzed for programmed death ligand1 (PD-L1) expression via immunohistochemistry.

Results
Patient Characteristics

Patients who were primarily refractory to ﬁrst-line therapy with
either VEGF-targeted TKIs or ICIs were identiﬁed from clinical
records (n ¼ 7; see Supplemental Table 1 in the online version).
The median patient age at diagnosis was 57 years (range, 39-63
years). All 7 patients were male and had clear cell histology (3 [43%]
with sarcomatoid differentiation, including 2 with additional
rhabdoid differentiation). Six patients (86%) had undergone prior
nephrectomy; 4 patients (57%) were classiﬁed as “intermediate risk”

3 (43%) were classiﬁed as “poor risk” according to the International
Metastatic Renal Cell Carcinoma Database Consortium criteria. Six
patients (86%) had pulmonary nodules, 3 (43%) had brain lesions,
4 (57%) had bone metastases, and 1 (14%) had liver lesions
(Supplemental Table 1 in the online version).
Samples were subjected to genomic analyses in 6 patients and for
analysis of PD-L1 expression in 5 patients (Supplemental Table 2 in
the online version). Five of the 6 patients tested (83%) had genomic
variants: 4 (67%) had loss of function in VHL, 2 (33%) had loss of
function in PBRM1, and 1 (17%) had loss of function in PTEN. Of
the 5 patients analyzed for PD-L1 expression, 1 (20%) stained
positive by immunohistochemistry.

Treatment Exposure
Regarding previous treatment exposure, 2 patients had prior
VEGF-targeted TKI therapy (sunitinib, pazopanib, or cabozantinib), 3 had prior ICI therapy with ipilimumab plus nivolumab
combination as ﬁrst-line therapy, and 2 patients had prior VEGFtargeted TKI and ICI therapy (Table 1). The median time to
progression on prior TKI or ICI therapy was 1.5 months (range,
0.8-3 months). Patients received the combination of lenvatinib plus
everolimus as either second-line (n ¼ 4; 57%) or third-line (n ¼ 3;
43%) therapy. Of note, 2 patients changed their treatment regimen
to lenvatinib plus everolimus due to toxicity with previous therapies
rather than to disease progression.
The patients were followed for up to 17 months after initiation
of lenvatinib plus everolimus combination therapy (range, 4-17
months). At the time of analysis (October 29, 2019), the 7 patients had received the combination treatment for a median of 7
months (Figure 1). At the time of this report (October 29, 2019),
1 patient remained on the combination therapy and had stable
disease at last follow-up. The reasons for discontinuation of
treatment in the other 6 patients were disease progression in 3
(50%), treatment-emergent adverse events in 2 (33%), and an
approved switch to a new treatment regimen for mRCC in 1
(16.7%).
The combination treatment was discontinued for a brief period
in 2 patients (5 days for patient 1 and 5 weeks for patient 3) and
then resumed when these 2 patients’ tumors began to rapidly
progress while off the regimen. Patient 1 experienced fatigue and
weight loss, which prompted discontinuation of the lenvatinib
plus everolimus regimen in preparation for ICI combination
(ipilimumab plus nivolumab) therapy. At 2 days after discontinuation of lenvatinib plus everolimus, he presented with a
headache, and subsequent magnetic resonance imaging showed
edema. Five days later, he resumed lenvatinib plus everolimus
treatment. He received lenvatinib plus everolimus for a total of
15 months and had an overall survival (OS) of 17 months
(Figure 1).
Patient 3 had a history of previous treatment with a VEGFtargeted TKI; after 1.5 months of treatment, pazopanib was discontinued because of disease progression and worsening liver lesions. He was then treated with cabozantinib for 2 weeks before
discontinuation due to the development of new skin lesions. He
was then started on therapy with lenvatinib plus everolimus as a
third-line treatment regimen on which the patient experienced a
best response of stable disease. However, due to fatigue and the
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Table 1 Treatment Exposure

Patient
1
3

4
5
7
2
6

Prior Treatment
(Line)
Prior TKI
Sunitinib (1)
Pazopanibb (1)
Cabozantinibd (2)
Prior ICI
Ipilimumab þ nivolumab (1)
Ipilimumab þ nivolumab (1)
Ipilimumab þ nivolumabd (1)
Prior TKI and ICI
Sunitinib (1)
Nivolumab þ lenvatinib (2)
Cabozantinibd (1)
Ipilimumab þ nivolumab (2)

Duration of
Line of
Discontinued
Prior Therapy LEN D EVE LEN D EVE
Reason for
Duration of
(mo)
Treatment
Treatment Discontinuation Therapy (mo)
0.8
1.5

15a
7c

Follow-Up
(mo)
17
9

Second
Third

Yes
Yes

PD
Started new
anticancer regimen

Second
Second
Second

Yes
No
Yes

AE
NA
AE

8
6þ
7

9
11þ
9þ

Third

Yes

PD

8

11

Third

Yes

PD

3

4

0.5
1
2
1
2
3
1.5
1.5

Abbreviations: AE ¼ adverse event; EVE ¼ everolimus; ICI ¼ immune checkpoint inhibitor; LEN ¼ lenvatinib; NA ¼ not applicable; PD ¼ progressive disease; TKI ¼ tyrosine kinase inhibitor.
a
Treatment was discontinued for 5 days due to toxicity, then resumed due to progression of brain metastasis.
b
Patient had mixed response.
c
Treatment was discontinued for 5 weeks because of the approval of nivolumab plus ipilimumab combination in mRCC but was later resumed due to progression of skin lesions on the ICI combination.
d
Discontinued because of toxicity rather than disease progression.

hope for an objective treatment response, treatment was discontinued and was replaced with the recently approved ICI
combination treatment for mRCC: ipilimumab plus nivolumab.
At the ﬁrst scan after initiation of this ICI combination therapy,
there was visible tumor shrinkage; however, the patient had
developed seizure-like episodes that were responsive to high-dose
steroids. Thus, ICI therapy was discontinued, and the patient
resumed treatment with lenvatinib plus everolimus. The patient
continued to receive lenvatinib plus everolimus for a cumulative
total of 7 months, with a reported best response of stable disease
and an OS of 9 months (Figure 1).

Treatment Outcomes
Of particular interest is the outcome of a patient (patient 1) who
had mRCC that was refractory to previous TKI therapy (sunitinib)
and who experienced rapid disease progression after discontinuation
of treatment with lenvatinib plus everolimus. He had discontinued
lenvatinib plus everolimus combination therapy due to toxicity and
exhibited marked disease progression 5 days later, followed by an
impressive and rapid response to treatment once the combination
regimen was resumed (Supplemental Figure 1 in the online version).
He had a best overall response of partial response (Figure 2B) and an
OS of 17 months.

Figure 1 Patients With Metastatic Renal Cell Carcinoma (mRCC) that Was Primarily Refractory to First-Line Therapy Were Identiﬁed
(n [ 7) and Treated With the Combination of Lenvatinib and Everolimus. Their Time on the Combination Therapy (Blue Bars)
and Their Efﬁcacy Outcomes are Shown
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Also of interest is the outcome of a patient refractory to previous
ICI combination therapy (ipilimumab plus nivolumab) who then
had a partial response to treatment with lenvatinib plus everolimus,
and whose treatment is ongoing. This patient (patient 5) presented
with a brain metastasis, started lenvatinib plus everolimus therapy,
and achieved a partial response after approximately 8 weeks
(Figure 2D). On follow-up (approximately 2 months later) of a
known brain lesion that had been irradiated, a brain scan showed a
small asymptomatic brain lesion, which was treated by gamma-knife
radiosurgery. At the time of this report, he was continuing to receive
treatment with lenvatinib plus everolimus and remained in stable
condition with an ongoing OS of >11 months.
Of the 7 patients treated with lenvatinib plus everolimus in this
case study, 3 (43%) had a partial response as the best response, 3
(43%) had stable disease as the best response, and 1 (14%) had
progressive disease. At the time of this report, all patients had
experienced disease progression, and 5 (71%) had died (Table 2).
Progression-free survival ranged from 3 to 15 months, and OS
ranged from 4 to 17 months. Of note, the OS has not been reached
for 2 patients because their survival is currently ongoing (>11 and
>9 months, respectively).

Discussion
The 7 cases presented here provide real-world data on the
combination of lenvatinib plus everolimus in patients with clear cell
mRCC whose disease appeared intrinsically refractory to front-line
TKI or ICI combination therapy. Patients with primary refractory
disease are a rare and difﬁcult-to-treat population with a poor
prognosis due to poor response to subsequent therapies.6,7

Therefore, our ﬁnding of a progression-free survival of 3 to 15
months in 6 of 7 primary refractory patients treated with lenvatinib
plus everolimus is encouraging.
In clinical practice, lenvatinib plus everolimus has demonstrated a
manageable tolerability proﬁle. Treatment-emergent adverse events
have been consistent with class effects typical of VEGF-targeted
TKIs and mTOR inhibitors, with no additive toxicity
observed17,19; the most frequently reported events are diarrhea,
decreased appetite, and fatigue.
Based on phase 1 and phase 2 trials in mRCC, this regimen has
been proposed as a preferred second-line treatment in patients with
intrinsic refractory disease and those with early disease progression.13 Lenvatinib blocks both VEGF- and FGF-driven angiogenesis, KIT-dependent angiogenesis, RET-fusion/RET-mutant
tumorigenesis, and VEGF-3eassociated lymphangiogenesis.12,20-23
Preclinical studies have attributed the synergistic antitumor activity of lenvatinib plus everolimus to potent enhancement of antiangiogenesis by simultaneous targeting of VEGF/FGF receptors and
the downstream mTOR pathway.24 Thus, our patients’ responses to
lenvatinib plus everolimus may be explained by increased expression
of FGF pathwayerelated genes; however, additional molecular
studies are needed to conﬁrm this.
Patients with mRCC who do not respond to early-line treatments
typically have rapid disease progression. Given the limited time for
additional therapies, it is critical to prioritize the most effective
therapies. With the approval of multiple subsequent lines of treatment based on clinical trials of different comparative arms, patient
characteristics, and treatment settings, it has been challenging to
choose the next line of treatment in patients with mRCC. We believe

Figure 2 Representative Images From 2 Patients With Primary Metastatic Renal Cell Carcinoma (mRCC) Refractory to Previous
Tyrosine Kinase Inhibitor (TKI) Therapy (Patient 1; A and B) or Immune Checkpoint Inhibitor (ICI) Therapy (Patient 5; C and D)
Who had a Partial Response after Lenvatinib Plus Everolimus Treatment. Images Shown are of the Pretreatment Scans (A
and C), With Tumors Clearly Visible, and the Posttreatment Scan (B and D), in which Tumor Size is Much Reduced
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Table 2 Treatment Outcomes
Most Recent
Prior Therapy

Patient

Best Response

Disease
Progression

PFSa (mo)

Deathb

OSa (mo)

Follow-Upa (mo)

1
2
3
4
5
6
7

PR
SD
SD
PR
PR
PD
SD

Yes
Yes
Yes
Yes
Yes
Yes
Yes

15
6
6
9
3
3
9

Yes
Yes
Yes
Yes
No
Yes
No

17
11
9
9
11þ
4
9þ

17
11
9
9
11þ
4
9þ

c

TKI

ICI

Abbreviations: ICI ¼ immune checkpoint inhibitor; OS ¼ overall survival; PFS ¼ progression-free survival; PD ¼ progressive disease; PR ¼ partial response; SD ¼ stable disease; TKI ¼ tyrosine
kinase inhibitor.
a
A conversion factor of 30.4375 was used to convert number of days into months; patients who were still alive at last follow-up (October 29, 2019) are indicated with a plus for OS, because survival
was ongoing at the time of this report.
b
Patient survival status as of last follow-up (October 29, 2019).
c
Patient 2 received lenvatinib plus nivolumab (TKI þ ICI) as last prior therapy.

that the case studies present here demonstrate that the combination of
lenvatinib and everolimus can be considered a second-line therapy
option for patients who are primarily refractory to VEGF-targeted
TKI and/or ICIs and warrants further investigation.

Conclusions
Our study demonstrates real-world evidence of lenvatinib plus
everolimus in patients with primary refractory disease. These 7
patients received a VEGF-targeted TKI (sunitinib, cabozantinib,
pazopanib) or ICI combination (ipilimumab plus nivolumab) as
ﬁrst-line treatment, making our data applicable to the current
treatment era. Because responses to subsequent lines of therapy in
the primary refractory patient population are rare, the use of lenvatinib plus everolimus in patients with intrinsically resistant clear
cell mRCC merit further study in this challenging group of patients
with a dismal prognosis.

Clinical Practice Points
 Patients with clear cell metastatic renal cell carcinoma (mRCC)

that is primarily refractory to ﬁrst-line treatment have a dismal
prognosis due to poor response to subsequent therapies.
 Moreover, there is limited guidance on second-line therapy for
patients with mRCC after progression on or following the
recently approved immune checkpoint inhibitor (ICI) combination therapy (ipilimumab þ nivolumab).
 In this case series, we report 7 patients with primary refractory
disease to either a tyrosine kinase inhibitor (TKI) or ICI combination therapy. These patients had clear cell mRCC that had
progressed following ﬁrst-line vascular endothelial growth factortargeted TKIs (n ¼ 4) or ICI combination therapy (n ¼ 3). All 7
patients were subsequently treated with lenvatinib (a multitargeted TKI) plus everolimus (a mammalian target of rapamycin
inhibitor) as either second-line or third-line therapy.
 All 3 patients who had failed ﬁrst-line TKI therapy experienced a
clinical beneﬁt of either partial response (PR; n ¼ 1) or stable
disease (SD; n ¼ 2) in response to treatment with lenvatinib plus
everolimus. Among the 4 patients who were primarily refractory
to ﬁrst-line ICI combination therapy, a clinical beneﬁt was
observed in 3 patients (PR, n ¼ 2; SD, n ¼ 1), and 1 patient
experienced disease progression.
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 In this case series, 6 of 7 patients with primary resistance to ﬁrst-

line TKI or ICI combination therapy beneﬁtted from subsequent
treatment with lenvatinib plus everolimus. These real-world data
suggest that lenvatinib plus everolimus may improve the prognosis of patients with intrinsically resistant clear cell mRCC and
thus merits careful consideration as a potential treatment option.
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Supplemental Data

Supplemental Table 1 Patient Characteristics
Age (y)

Sex

Previous
Nephrectomy

1

62

Male

Yes

2

54

Male

Yes

3

39

Male

Yes

4

63

Male

5

56

6
7

63
57

Patient

Histology

IMDC Risk Group

Sites of Metastasisa

Intermediate

Lungs, lymph nodes

Intermediate

Lungs, bones, brain

Poor

Lungs, liver

Yes

Clear cell þ rhabdoid and
sarcomatoid transformation
Clear cell þ rhabdoid and
sarcomatoid transformation
Clear cell þ rhabdoid
transformation
Clear cell

Intermediate

Male

Yes

Clear cell

Poor

Male
Male

No
Yes

Clear cell
Clear cell with sarcomatoid
changes

Poor
Intermediate

Lungs, lymph nodes,
nephrectomy bed nodule
Lungs, lymph nodes, brain,
bones, adrenal glands
Lungs, bones, brain
Lymph nodes, bones

Abbreviation: IMDC ¼ International Metastatic Renal Cell Carcinoma Database Consortium.
a
At the time of initiation of lenvatinib plus everolimus treatment.

Supplemental Table 2 Genomic and PDL-1 Data
Patient

Genomic Variants

Copy Number Variations

PDL-1 Expression

PBRM1 LOF
VHL LOF
PTEN LOF
ARID1A LOF
LIFR frameshift
Not assessed
VHL LOF
SETD2 LOF
ARID2 GOF
VHL LOF
PBRM1 LOF
VHL LOF
PIK3R1 LOF
KDM5C LOF

None

Not assessed

Not assessed
CDKN1B CNG

Not assessed
Negative

None
None
PTEN CNL
CDKN2A CNL
CDKN2B CNL
MTAP CNL
CDKN2A CNL
CDKN2B CNL
MTAP CNL

Negative
Positive
Negative

1

2
3

4
5
6

7

None

Abbreviations: CNG ¼ copy number gain; CNL ¼ copy number loss; GOF ¼ gain of function; LOF ¼ loss of function; PDL-1 ¼ programmed death ligand-1.
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Supplemental Figure 1 Magnetic Resonance Imaging (MRI) Results for Patient 1 With Metastatic Renal Cell Carcinoma (mRCC) Who
Received Lenvatinib Plus Everolimus Treatment. (A) Brain MRI Showing the Tumor Size (Mid-right Side of the
Brain) after Treatment for 2 Weeks. (B) Brain MRI Performed 5 days After Discontinuation of Treatment due to
Toxicity Showing Rapid Tumor Regrowth. (C) Brain MRI Performed Approximately 2 weeks after Resumption
of Lenvatinib Plus Everolimus Treatment Showing Rapid Improvement
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